Cryptosporidium genetics really works! Latest cross explains why tb drug failed in crypto clinical trial. Widespread genomic heterogeneity at the type II NAD(P)H dehydrogenase locus predisposes Cryptosporidium to clofazimine resistance @millseba https://t.co/3g7zSjBYpP
Early GRAD STUDENT $
Hertz Fellowship-- applied science including applied biology in the US. First years, college seniors, and gap year students eligible. 5 yr, $250k. Limited list of applicant institutions but you can ask them to consider adding yours.
https://t.co/4u3Lzdak4J
Blood, sweat, and beers: investigating mosquito biting preferences amidst noise and intoxication in a cross-sectional cohort study at a large music festival https://t.co/Nn6owQRWPz
Cool approach to use bi-specifics to target cell surface receptors for therapy: ALK1-BMPRII agonism by clustering bispecific antibodies treats hereditary hemorrhagic telangiectasia https://t.co/qYVOMH3NLC
Thrilled to share the next chapter in my career — I’ve been named the inaugural Chair of the Department of Dermatology at Mass General Brigham (MGB).
It’s an incredible honor to lead such an accomplished, innovative team—arguably the most forward-thinking in our field.
For those with an interest in enteric infections (or if you have had Beaver Fever) - this commentary summarizes recent studies on the potential benefits of Giardia. Public offering of shares in ParasitesAreUs to come.... https://t.co/HOWnEvcYlk
New in @SciImmunology!
@EmilyAunins, Dr. Anthony Phan, and their colleagues in the @WeissmanLab and Hunter Lab (@KingOfPathogens) used lipid nanoparticles encoding IL-12 to boost CD8 T cell responses to mRNA vaccines.
📃 https://t.co/0chkzWVDqm
🎧 https://t.co/vvDVzU06M6
What a week: I was lucky enough to get an ERC Advanced Grant, a Wellcome Trust Discovery award, and my fab colleagues at Inflammazoom nominated me for this BSI award. Thank you so much https://t.co/whWPWI3Fv6